Premium
Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: A CALGB phase I study
Author(s) -
Amrein Philip C.,
Davis Roger B.,
Mayer Robert J.,
Schiffer Charles A.
Publication year - 1990
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830350203
Subject(s) - mitoxantrone , medicine , chemotherapy , refractory (planetary science) , toxicity , myeloid leukemia , surgery , phases of clinical research , leukemia , gastroenterology , physics , astrobiology
Twenty‐one patients with relapsed or refractory acute myeloid leukemia (AML) were treated with mitoxantrone (12 mg/m 2 /day, days 1–3) and diaziquone (continuous infusion days 1–5). The dosage of diaziquone was increased for sequential cohorts of seven patients from 20 mg/m 2 /day to 24 mg/m 2 /day, and finally to 28 mg/m 2 /day to determine the maximum tolerated dose for this chemotherapy combination. Myelosuppression was the dose‐limiting toxicity. The median time to recovery of blood counts was greater at the highest dose of diaziquone (48 days) than at the lower two doses (31 and 28 days). Other toxic effects were minimal. Overall, 9/21 (43%, 95% confidence interval, 0.22 to 0.66) patients achieved complete remission. We conclude that this combination of drugs shows sufficient antileukemic activity with acceptable toxicity to warrant further trials.